Kros.Ns
KROS.NS is an Indian company engaged in the manufacturing and supply of auto, truck, and motorcycle parts, primarily serving the automotive industry.
Business. Keros Therapeutics Inc (KROS.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
9 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Keros Therapeutics Inc (KROS.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
KROS.NS maintains a strong liquidity position, with a current ratio of 3.21, indicating the company can easily cover its short-term liabilities with its current assets. The company also holds INR 804.34 million in cash and equivalents, which provides a buffer against short-term obligations. However, the operating cash flow is negative at INR -320.59 million, suggesting that the company's core operations are not currently generating positive cash flow. Free cash flow, on the other hand, is positive at INR 265.18 million, indicating that the company has sufficient cash flow to fund operations and potentially invest in growth after capital expenditures.
In terms of profitability, KROS.NS reports a return on equity (ROE) of 11.05% and a return on assets (ROA) of 8.38%, both of which are strong indicators of efficient use of equity and assets to generate profits. The company's gross profit of INR 2.13 billion and operating income of INR 744.08 million further support its profitability. The debt-to-equity ratio of 0.08 suggests that the company is not heavily leveraged and has a conservative capital structure.
KROS.NS operates in a single business segment focused on auto, truck, and motorcycle parts, with no disclosed geographic diversification. The company's revenue is concentrated in this segment, and there is no information provided on geographic revenue distribution. This concentration may expose the company to risks associated with the performance of the automotive industry and regional economic conditions.
The company's growth trajectory is not explicitly outlined in the available data, but the positive free cash flow and strong ROE suggest potential for reinvestment and expansion. The capital expenditure of INR -283.56 million indicates that the company is investing in its operations, which could support future growth. However, the negative operating cash flow may limit the company's ability to fund growth initiatives without external financing.
KROS.NS is currently assessed as having low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and substantial cash reserves reduce the likelihood of near-term dilution. However, the negative operating cash flow could become a concern if it persists, potentially leading to the need for additional financing and possible dilution.
There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The company's financial statements do not indicate any major legal, regulatory, or operational issues that would affect its performance in the near term.
- KROS.NS has a strong liquidity position with a current ratio of 3.21 and INR 804.34 million in cash and equivalents.
- The company's ROE of 11.05% and ROA of 8.38% indicate efficient use of equity and assets to generate profits.
- KROS.NS is not heavily leveraged, with a debt-to-equity ratio of 0.08, suggesting a conservative capital structure.
- The company's free cash flow of INR 265.18 million supports potential reinvestment and expansion.
- The negative operating cash flow of INR -320.59 million may limit the company's ability to fund growth without external financing.
- The company is assessed as having low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
- Director · Stock Option (right to buy) → Common StockAcquired 7 433 @ $10,50grant · 2026-06-03
- Director, CHIEF EXECUTIVE OFFICER · Employee Stock Option (Right to Buy) → Common StockDisposed 55 000 @ $0,30exercise · 2026-04-02
- Director · Stock Option (Right to Buy) → Common StockAcquired 14 788 @ $11,35grant · 2026-03-09
- CHIEF FINANCIAL OFFICER · Employee Stock Option (Right to Buy) → Common StockAcquired 60 000 @ $15,52grant · 2026-02-24
- Director, CHIEF EXECUTIVE OFFICER · Employee Stock Option (Right to Buy) → Common StockAcquired 217 000 @ $15,52grant · 2026-02-24
- Director, CHIEF EXECUTIVE OFFICER · Employee Stock Option (right to buy) → Common StockAcquired 100 000 @ $15,52grant · 2026-02-24
- Chief Legal Officer · Employee Stock Option (Right to Buy) → Common StockAcquired 80 000 @ $15,52grant · 2026-02-24
- Chief Scientific Officer · Employee Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $15,52grant · 2026-02-24
- Director, CHIEF EXECUTIVE OFFICER · Employee Stock Option (right to buy) → Common StockAcquired 62 500 @ $63,61grant · 2026-01-07
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- KROS.NS Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2024-06-300,00 %$115M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2025-12-310,00 %$31M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director · Common StockBought 1 000 @ $10,19$10K · 2026-06-15
- Director · Common StockSold 550 @ $10,04$6K · 2026-06-11
- Director · Common StockSold 2 625 @ $10,73$28K · 2026-06-04
- Director · Common StockSold 2 625 @ $10,72$28K · 2026-06-04
- Director · Common StockSold 2 625 @ $10,73$28K · 2026-06-04
- Director · Common StockOther 7 142 · 2026-06-03
- Director · Common StockOther 7 142 · 2026-06-03
- Director · Common StockOther 7 142 · 2026-06-03
- Director · Common StockOther 7 142 · 2026-06-03
- Director · Common StockOther 7 142 · 2026-06-03
- Director · Common StockBought 1 000 @ $10,58$11K · 2026-05-15
- Director · Common StockBought 1 000 @ $11,70$12K · 2026-04-15
- Director, CHIEF EXECUTIVE OFFICER · Common StockOther 55 000 @ $0,30$16K · 2026-04-02
- Director · Common StockOther 13 215 · 2026-03-09
- Director · Common StockBought 2 000 @ $11,21$22K · 2026-03-09
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 7 015 @ $16,17$113K · 2026-02-19
- Chief Science Officer · Common StockSold 3 873 @ $16,35$63K · 2026-02-18
- SVP, General Counsel · Common StockSold 4 745 @ $16,35$78K · 2026-02-18
- CHIEF FINANCIAL OFFICER · Common StockSold 4 739 @ $16,35$77K · 2026-02-18
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -21.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -45.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -48.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.12xDerived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 146.0%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -19.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 146.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -47.0%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -25.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 166.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 146.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 132.0%Derived (calculated)
- Net margin (FY 2025-12-31): 35.7%Derived (calculated)
- Return on equity (FY 2025-12-31): 28.7%Derived (calculated)
- Return on assets (FY 2025-12-31): 25.7%Derived (calculated)
- Current ratio (FY 2025-12-31): 15.45xDerived (calculated)
- Cash & equivalents (annual): USD 287.42MSEC XBRL filing
- Revenue (annual): USD 243.86MSEC XBRL filing
- Operating income (annual): USD 67.57MSEC XBRL filing
- Capex (annual): USD 1.55MSEC XBRL filing
- Total assets (annual): USD 338.02MSEC XBRL filing
- Total liabilities (annual): USD 34.89MSEC XBRL filing
- Pre-tax income (annual): USD 91.9MSEC XBRL filing
- R&D expense (annual): USD 129.64MSEC XBRL filing